Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

Investigation of ( S)-(-)-Acidomycin: A Selective Antimycobacterial Natural Product That Inhibits Biotin Synthase.

Bockman MR, Engelhart CA, Cramer JD, Howe MD, Mishra NK, Zimmerman M, Larson P, Alvarez-Cabrera N, Park SW, Boshoff HIM, Bean JM, Young VG Jr, Ferguson DM, Dartois V, Jarrett JT, Schnappinger D, Aldrich CC.

ACS Infect Dis. 2019 Feb 4. doi: 10.1021/acsinfecdis.8b00345. [Epub ahead of print]

PMID:
30652474
2.

Optimization of N-benzyl-5-nitrofuran-2-carboxamide as an antitubercular agent.

Gallardo-Macias R, Kumar P, Jaskowski M, Richmann T, Shrestha R, Russo R, Singleton E, Zimmerman MD, Ho HP, Dartois V, Connell N, Alland D, Freundlich JS.

Bioorg Med Chem Lett. 2019 Feb 15;29(4):601-606. doi: 10.1016/j.bmcl.2018.12.053. Epub 2018 Dec 24.

PMID:
30600207
3.

Synergistic Lethality of a Binary Inhibitor of Mycobacterium tuberculosis KasA.

Kumar P, Capodagli GC, Awasthi D, Shrestha R, Maharaja K, Sukheja P, Li SG, Inoyama D, Zimmerman M, Ho Liang HP, Sarathy J, Mina M, Rasic G, Russo R, Perryman AL, Richmann T, Gupta A, Singleton E, Verma S, Husain S, Soteropoulos P, Wang Z, Morris R, Porter G, Agnihotri G, Salgame P, Ekins S, Rhee KY, Connell N, Dartois V, Neiditch MB, Freundlich JS, Alland D.

MBio. 2018 Dec 18;9(6). pii: e02101-17. doi: 10.1128/mBio.02101-17.

4.

An explant technique for high-resolution imaging and manipulation of mycobacterial granulomas.

Cronan MR, Matty MA, Rosenberg AF, Blanc L, Pyle CJ, Espenschied ST, Rawls JF, Dartois V, Tobin DM.

Nat Methods. 2018 Dec;15(12):1098-1107. doi: 10.1038/s41592-018-0215-8. Epub 2018 Nov 30.

PMID:
30504889
5.

High-resolution mapping of fluoroquinolones in TB rabbit lesions reveals specific distribution in immune cell types.

Blanc L, Daudelin IB, Podell BK, Chen PY, Zimmerman M, Martinot AJ, Savic RM, Prideaux B, Dartois V.

Elife. 2018 Nov 14;7. pii: e41115. doi: 10.7554/eLife.41115.

6.

Storage lipid studies in tuberculosis reveal that foam cell biogenesis is disease-specific.

Guerrini V, Prideaux B, Blanc L, Bruiners N, Arrigucci R, Singh S, Ho-Liang HP, Salamon H, Chen PY, Lakehal K, Subbian S, O'Brien P, Via LE, Barry CE 3rd, Dartois V, Gennaro ML.

PLoS Pathog. 2018 Aug 30;14(8):e1007223. doi: 10.1371/journal.ppat.1007223. eCollection 2018 Aug.

7.

Kasugamycin potentiates rifampicin and limits emergence of resistance in Mycobacterium tuberculosis by specifically decreasing mycobacterial mistranslation.

Chaudhuri S, Li L, Zimmerman M, Chen Y, Chen YX, Toosky MN, Gardner M, Pan M, Li YY, Kawaji Q, Zhu JH, Su HW, Martinot AJ, Rubin EJ, Dartois VA, Javid B.

Elife. 2018 Aug 28;7. pii: e36782. doi: 10.7554/eLife.36782.

8.

TB drug susceptibility is more than MIC.

Dick T, Dartois V.

Nat Microbiol. 2018 Sep;3(9):971-972. doi: 10.1038/s41564-018-0226-3. No abstract available.

PMID:
30143801
9.

Impact of immunopathology on the antituberculous activity of pyrazinamide.

Blanc L, Sarathy JP, Alvarez Cabrera N, O'Brien P, Dias-Freedman I, Mina M, Sacchettini J, Savic RM, Gengenbacher M, Podell BK, Prideaux B, Ioerger T, Dick T, Dartois V.

J Exp Med. 2018 Aug 6;215(8):1975-1986. doi: 10.1084/jem.20180518. Epub 2018 Jul 17.

10.

Imaging and spatially resolved quantification of drug distribution in tissues by mass spectrometry.

Prideaux B, Lenaerts A, Dartois V.

Curr Opin Chem Biol. 2018 Jun;44:93-100. doi: 10.1016/j.cbpa.2018.05.007. Epub 2018 Jun 27. Review.

PMID:
29957376
11.

Indolyl Azaspiroketal Mannich Bases Are Potent Antimycobacterial Agents with Selective Membrane Permeabilizing Effects and in Vivo Activity.

Nyantakyi SA, Li M, Gopal P, Zimmerman M, Dartois V, Gengenbacher M, Dick T, Go ML.

J Med Chem. 2018 Jul 12;61(13):5733-5750. doi: 10.1021/acs.jmedchem.8b00777. Epub 2018 Jun 25.

12.

Teicoplanin - Tigecycline Combination Shows Synergy Against Mycobacterium abscessus.

Aziz DB, Teo JWP, Dartois V, Dick T.

Front Microbiol. 2018 May 11;9:932. doi: 10.3389/fmicb.2018.00932. eCollection 2018.

13.
14.

Matrix metalloproteinase inhibitors enhance the efficacy of frontline drugs against Mycobacterium tuberculosis.

Xu Y, Wang L, Zimmerman MD, Chen KY, Huang L, Fu DJ, Kaya F, Rakhilin N, Nazarova EV, Bu P, Dartois V, Russell DG, Shen X.

PLoS Pathog. 2018 Apr 26;14(4):e1006974. doi: 10.1371/journal.ppat.1006974. eCollection 2018 Apr.

15.

Targeting protein biotinylation enhances tuberculosis chemotherapy.

Tiwari D, Park SW, Essawy MM, Dawadi S, Mason A, Nandakumar M, Zimmerman M, Mina M, Ho HP, Engelhart CA, Ioerger T, Sacchettini JC, Rhee K, Ehrt S, Aldrich CC, Dartois V, Schnappinger D.

Sci Transl Med. 2018 Apr 25;10(438). pii: eaal1803. doi: 10.1126/scitranslmed.aal1803.

PMID:
29695454
16.

Visualization of Mycobacterial Biomarkers and Tuberculosis Drugs in Infected Tissue by MALDI-MS Imaging.

Blanc L, Lenaerts A, Dartois V, Prideaux B.

Anal Chem. 2018 May 15;90(10):6275-6282. doi: 10.1021/acs.analchem.8b00985. Epub 2018 Apr 26.

17.

NTM drug discovery: status, gaps and the way forward.

Wu ML, Aziz DB, Dartois V, Dick T.

Drug Discov Today. 2018 Aug;23(8):1502-1519. doi: 10.1016/j.drudis.2018.04.001. Epub 2018 Apr 7. Review.

18.

Pharmacokinetics of rifapentine and rifampin in a rabbit model of tuberculosis and correlation with clinical trial data.

Rifat D, Prideaux B, Savic RM, Urbanowski ME, Parsons TL, Luna B, Marzinke MA, Ordonez AA, DeMarco VP, Jain SK, Dartois V, Bishai WR, Dooley KE.

Sci Transl Med. 2018 Apr 4;10(435). pii: eaai7786. doi: 10.1126/scitranslmed.aai7786.

PMID:
29618565
19.

Linezolid pharmacokinetics in MDR-TB: a systematic review, meta-analysis and Monte Carlo simulation.

Millard J, Pertinez H, Bonnett L, Hodel EM, Dartois V, Johnson JL, Caws M, Tiberi S, Bolhuis M, Alffenaar JC, Davies G, Sloan DJ.

J Antimicrob Chemother. 2018 Jul 1;73(7):1755-1762. doi: 10.1093/jac/dky096.

20.

Verapamil Targets Membrane Energetics in Mycobacterium tuberculosis.

Chen C, Gardete S, Jansen RS, Shetty A, Dick T, Rhee KY, Dartois V.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e02107-17. doi: 10.1128/AAC.02107-17. Print 2018 May.

21.

Novel Pyrimidines as Antitubercular Agents.

Inoyama D, Paget SD, Russo R, Kandasamy S, Kumar P, Singleton E, Occi J, Tuckman M, Zimmerman MD, Ho HP, Perryman AL, Dartois V, Connell N, Freundlich JS.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e02063-17. doi: 10.1128/AAC.02063-17. Print 2018 Mar.

22.

Whole-Cell Screen of Fragment Library Identifies Gut Microbiota Metabolite Indole Propionic Acid as Antitubercular.

Negatu DA, Liu JJJ, Zimmerman M, Kaya F, Dartois V, Aldrich CC, Gengenbacher M, Dick T.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e01571-17. doi: 10.1128/AAC.01571-17. Print 2018 Mar.

23.

Extreme Drug Tolerance of Mycobacterium tuberculosis in Caseum.

Sarathy JP, Via LE, Weiner D, Blanc L, Boshoff H, Eugenin EA, Barry CE 3rd, Dartois VA.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e02266-17. doi: 10.1128/AAC.02266-17. Print 2018 Feb.

24.

Pyrazinoic Acid Inhibits Mycobacterial Coenzyme A Biosynthesis by Binding to Aspartate Decarboxylase PanD.

Gopal P, Nartey W, Ragunathan P, Sarathy J, Kaya F, Yee M, Setzer C, Manimekalai MSS, Dartois V, Grüber G, Dick T.

ACS Infect Dis. 2017 Nov 10;3(11):807-819. doi: 10.1021/acsinfecdis.7b00079. Epub 2017 Oct 18.

25.

Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors.

Bartelink IH, Prideaux B, Krings G, Wilmes L, Lee PRE, Bo P, Hann B, Coppé JP, Heditsian D, Swigart-Brown L, Jones EF, Magnitsky S, Keizer RJ, de Vries N, Rosing H, Pawlowska N, Thomas S, Dhawan M, Aggarwal R, Munster PN, Esserman LJ, Ruan W, Wu AHB, Yee D, Dartois V, Savic RM, Wolf DM, van 't Veer L.

Breast Cancer Res. 2017 Sep 11;19(1):107. doi: 10.1186/s13058-017-0896-4.

26.

NOS2-deficient mice with hypoxic necrotizing lung lesions predict outcomes of tuberculosis chemotherapy in humans.

Gengenbacher M, Duque-Correa MA, Kaiser P, Schuerer S, Lazar D, Zedler U, Reece ST, Nayyar A, Cole ST, Makarov V, Barry Iii CE, Dartois V, Kaufmann SHE.

Sci Rep. 2017 Aug 18;7(1):8853. doi: 10.1038/s41598-017-09177-2.

27.

Comparing efficacies of moxifloxacin, levofloxacin and gatifloxacin in tuberculosis granulomas using a multi-scale systems pharmacology approach.

Pienaar E, Sarathy J, Prideaux B, Dietzold J, Dartois V, Kirschner DE, Linderman JJ.

PLoS Comput Biol. 2017 Aug 17;13(8):e1005650. doi: 10.1371/journal.pcbi.1005650. eCollection 2017 Aug.

28.

Unraveling Drug Penetration of Echinocandin Antifungals at the Site of Infection in an Intra-abdominal Abscess Model.

Zhao Y, Prideaux B, Nagasaki Y, Lee MH, Chen PY, Blanc L, Ho H, Clancy CJ, Nguyen MH, Dartois V, Perlin DS.

Antimicrob Agents Chemother. 2017 Sep 22;61(10). pii: e01009-17. doi: 10.1128/AAC.01009-17. Print 2017 Oct.

29.

Coadministration of Allopurinol To Increase Antimycobacterial Efficacy of Pyrazinamide as Evaluated in a Whole-Blood Bactericidal Activity Model.

Naftalin CM, Verma R, Gurumurthy M, Lu Q, Zimmerman M, Yeo BCM, Tan KH, Lin W, Yu B, Dartois V, Paton NI.

Antimicrob Agents Chemother. 2017 Sep 22;61(10). pii: e00482-17. doi: 10.1128/AAC.00482-17. Print 2017 Oct.

30.

Ethambutol Partitioning in Tuberculous Pulmonary Lesions Explains Its Clinical Efficacy.

Zimmerman M, Lestner J, Prideaux B, O'Brien P, Dias-Freedman I, Chen C, Dietzold J, Daudelin I, Kaya F, Blanc L, Chen PY, Park S, Salgame P, Sarathy J, Dartois V.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00924-17. doi: 10.1128/AAC.00924-17. Print 2017 Sep.

31.

An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions.

Sarathy JP, Liang HH, Weiner D, Gonzales J, Via LE, Dartois V.

J Vis Exp. 2017 May 8;(123). doi: 10.3791/55559.

32.

Nitric oxide prevents a pathogen-permissive granulocytic inflammation during tuberculosis.

Mishra BB, Lovewell RR, Olive AJ, Zhang G, Wang W, Eugenin E, Smith CM, Phuah JY, Long JE, Dubuke ML, Palace SG, Goguen JD, Baker RE, Nambi S, Mishra R, Booty MG, Baer CE, Shaffer SA, Dartois V, McCormick BA, Chen X, Sassetti CM.

Nat Microbiol. 2017 May 15;2:17072. doi: 10.1038/nmicrobiol.2017.72.

33.

Rifabutin Is Active against Mycobacterium abscessus Complex.

Aziz DB, Low JL, Wu ML, Gengenbacher M, Teo JWP, Dartois V, Dick T.

Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e00155-17. doi: 10.1128/AAC.00155-17. Print 2017 Jun.

34.

In Vivo-Selected Pyrazinoic Acid-Resistant Mycobacterium tuberculosis Strains Harbor Missense Mutations in the Aspartate Decarboxylase PanD and the Unfoldase ClpC1.

Gopal P, Tasneen R, Yee M, Lanoix JP, Sarathy J, Rasic G, Li L, Dartois V, Nuermberger E, Dick T.

ACS Infect Dis. 2017 Jul 14;3(7):492-501. doi: 10.1021/acsinfecdis.7b00017. Epub 2017 Mar 16.

35.

New Evidence for the Complexity of the Population Structure of Mycobacterium tuberculosis Increases the Diagnostic and Biologic Challenges.

Dartois V, Saito K, Warrier T, Nathan C.

Am J Respir Crit Care Med. 2016 Dec 15;194(12):1448-1451. No abstract available.

36.

Pyrazinamide Resistance Is Caused by Two Distinct Mechanisms: Prevention of Coenzyme A Depletion and Loss of Virulence Factor Synthesis.

Gopal P, Yee M, Sarathy J, Low JL, Sarathy JP, Kaya F, Dartois V, Gengenbacher M, Dick T.

ACS Infect Dis. 2016 Sep 9;2(9):616-626. Epub 2016 Aug 8.

37.

Essential but Not Vulnerable: Indazole Sulfonamides Targeting Inosine Monophosphate Dehydrogenase as Potential Leads against Mycobacterium tuberculosis.

Park Y, Pacitto A, Bayliss T, Cleghorn LA, Wang Z, Hartman T, Arora K, Ioerger TR, Sacchettini J, Rizzi M, Donini S, Blundell TL, Ascher DB, Rhee K, Breda A, Zhou N, Dartois V, Jonnala SR, Via LE, Mizrahi V, Epemolu O, Stojanovski L, Simeons F, Osuna-Cabello M, Ellis L, MacKenzie CJ, Smith AR, Davis SH, Murugesan D, Buchanan KI, Turner PA, Huggett M, Zuccotto F, Rebollo-Lopez MJ, Lafuente-Monasterio MJ, Sanz O, Diaz GS, Lelièvre J, Ballell L, Selenski C, Axtman M, Ghidelli-Disse S, Pflaumer H, Bösche M, Drewes G, Freiberg GM, Kurnick MD, Srikumaran M, Kempf DJ, Green SR, Ray PC, Read K, Wyatt P, Barry CE 3rd, Boshoff HI.

ACS Infect Dis. 2017 Jan 13;3(1):18-33. doi: 10.1021/acsinfecdis.6b00103. Epub 2016 Oct 17.

38.

Prediction of Drug Penetration in Tuberculosis Lesions.

Sarathy JP, Zuccotto F, Hsinpin H, Sandberg L, Via LE, Marriner GA, Masquelin T, Wyatt P, Ray P, Dartois V.

ACS Infect Dis. 2016 Aug 12;2(8):552-63. doi: 10.1021/acsinfecdis.6b00051. Epub 2016 Jul 6.

39.

Bedaquiline and Pyrazinamide Treatment Responses Are Affected by Pulmonary Lesion Heterogeneity in Mycobacterium tuberculosis Infected C3HeB/FeJ Mice.

Irwin SM, Prideaux B, Lyon ER, Zimmerman MD, Brooks EJ, Schrupp CA, Chen C, Reichlen MJ, Asay BC, Voskuil MI, Nuermberger EL, Andries K, Lyons MA, Dartois V, Lenaerts AJ.

ACS Infect Dis. 2016 Apr 8;2(4):251-267. Epub 2016 Feb 24.

40.

Novel Cephalosporins Selectively Active on Nonreplicating Mycobacterium tuberculosis.

Gold B, Smith R, Nguyen Q, Roberts J, Ling Y, Lopez Quezada L, Somersan S, Warrier T, Little D, Pingle M, Zhang D, Ballinger E, Zimmerman M, Dartois V, Hanson P, Mitscher LA, Porubsky P, Rogers S, Schoenen FJ, Nathan C, Aubé J.

J Med Chem. 2016 Jul 14;59(13):6027-44. doi: 10.1021/acs.jmedchem.5b01833. Epub 2016 Jun 17.

41.

High Systemic Exposure of Pyrazinoic Acid Has Limited Antituberculosis Activity in Murine and Rabbit Models of Tuberculosis.

Lanoix JP, Tasneen R, O'Brien P, Sarathy J, Safi H, Pinn M, Alland D, Dartois V, Nuermberger E.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):4197-205. doi: 10.1128/AAC.03085-15. Print 2016 Jul.

42.

Immune activation of the host cell induces drug tolerance in Mycobacterium tuberculosis both in vitro and in vivo.

Liu Y, Tan S, Huang L, Abramovitch RB, Rohde KH, Zimmerman MD, Chen C, Dartois V, VanderVen BC, Russell DG.

J Exp Med. 2016 May 2;213(5):809-25. doi: 10.1084/jem.20151248. Epub 2016 Apr 25.

43.

Inflammatory signaling in human tuberculosis granulomas is spatially organized.

Marakalala MJ, Raju RM, Sharma K, Zhang YJ, Eugenin EA, Prideaux B, Daudelin IB, Chen PY, Booty MG, Kim JH, Eum SY, Via LE, Behar SM, Barry CE 3rd, Mann M, Dartois V, Rubin EJ.

Nat Med. 2016 May;22(5):531-8. doi: 10.1038/nm.4073. Epub 2016 Apr 4.

44.

Adjunctive Phosphodiesterase-4 Inhibitor Therapy Improves Antibiotic Response to Pulmonary Tuberculosis in a Rabbit Model.

Subbian S, Tsenova L, Holloway J, Peixoto B, O'Brien P, Dartois V, Khetani V, Zeldis JB, Kaplan G.

EBioMedicine. 2016 Jan 14;4:104-14. doi: 10.1016/j.ebiom.2016.01.015. eCollection 2016 Feb.

45.

Statin adjunctive therapy shortens the duration of TB treatment in mice.

Dutta NK, Bruiners N, Pinn ML, Zimmerman MD, Prideaux B, Dartois V, Gennaro ML, Karakousis PC.

J Antimicrob Chemother. 2016 Jun;71(6):1570-7. doi: 10.1093/jac/dkw014. Epub 2016 Feb 21.

46.

Linezolid Trough Concentrations Correlate with Mitochondrial Toxicity-Related Adverse Events in the Treatment of Chronic Extensively Drug-Resistant Tuberculosis.

Song T, Lee M, Jeon HS, Park Y, Dodd LE, Dartois V, Follman D, Wang J, Cai Y, Goldfeder LC, Olivier KN, Xie Y, Via LE, Cho SN, Barry CE 3rd, Chen RY.

EBioMedicine. 2015 Oct 9;2(11):1627-33. doi: 10.1016/j.ebiom.2015.09.051. eCollection 2015 Nov.

47.

Development and validation of LC-ESI-MS/MS method for analysis of moxifloxacin and levofloxacin in serum of multidrug-resistant tuberculosis patients: Potential application as therapeutic drug monitoring tool in medical diagnosis.

Lee SJ, Desta KT, Eum SY, Dartois V, Cho SN, Bae DW, Shin SC.

J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Jan 15;1009-1010:138-43. doi: 10.1016/j.jchromb.2015.11.058. Epub 2015 Dec 8.

PMID:
26730550
48.

In silico evaluation and exploration of antibiotic tuberculosis treatment regimens.

Pienaar E, Dartois V, Linderman JJ, Kirschner DE.

BMC Syst Biol. 2015 Nov 14;9:79. doi: 10.1186/s12918-015-0221-8.

49.

Selective Inactivity of Pyrazinamide against Tuberculosis in C3HeB/FeJ Mice Is Best Explained by Neutral pH of Caseum.

Lanoix JP, Ioerger T, Ormond A, Kaya F, Sacchettini J, Dartois V, Nuermberger E.

Antimicrob Agents Chemother. 2015 Nov 16;60(2):735-43. doi: 10.1128/AAC.01370-15. Print 2016 Feb.

50.

Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis.

Tasneen R, Betoudji F, Tyagi S, Li SY, Williams K, Converse PJ, Dartois V, Yang T, Mendel CM, Mdluli KE, Nuermberger EL.

Antimicrob Agents Chemother. 2015 Oct 26;60(1):270-7. doi: 10.1128/AAC.01691-15. Print 2016 Jan.

Supplemental Content

Loading ...
Support Center